A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia
Connor, KM, Mahoney, E, Jackson, S, Hutzelmann, J, Zhao, X, Jia, N, Snyder, E, Snavely, D, Michelson, D, Roth, T, Herring, WJLanguage:
english
Journal:
International Journal of Neuropsychopharmacology
DOI:
10.1093/ijnp/pyw022
Date:
March, 2016
File:
PDF, 707 KB
english, 2016